2,108 research outputs found

    A commentary on standardization in the Semantic Web, Common Logic and MultiAgent Systems

    Get PDF
    Given the ubiquity of the Web, the Semantic Web (SW) offers MultiAgent Systems (MAS) a most wide-ranging platform by which they could intercommunicate. It can be argued however that MAS require levels of logic that the current Semantic Web has yet to provide. As ISO Common Logic (CL) ISO/IEC IS 24707:2007 provides a firstorder logic capability for MAS in an interoperable way, it seems natural to investigate how CL may itself integrate with the SW thus providing a more expressive means by which MAS can interoperate effectively across the SW. A commentary is accordingly presented on how this may be achieved. Whilst it notes that certain limitations remain to be addressed, the commentary proposes that standardising the SW with CL provides the vehicle by which MAS can achieve their potential.</p

    Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials

    Get PDF
    Background: Adenosine administered as an adjunct to reperfusion can reduce coronary no-reflow and limit myocardial infarct (MI) size in ST-segment elevation myocardial infarction (STEMI) patients. Whether adjunctive adenosine therapy can improve clinical outcomes in reperfused STEMI patients is not clear and is investigated in this meta-analysis of 13 randomized controlled trials (RCTs). Methods: We performed an up-to-date search for all RCTs investigating adenosine as an adjunct to reperfusion in STEMI patients. We calculated pooled relative risks using a fixed-effect meta-analysis assessing the impact of adjunctive adenosine therapy on major clinical endpoint including all-cause mortality, non-fatal myocardial infarction, and heart failure. Surrogate markers of reperfusion were also analyzed. Results: 13 RCTs (4273 STEMI patients) were identified and divided into 2 subgroups: intracoronary adenosine versus control (8 RCTs) and intravenous adenosine versus control (5 RCTs). In patients administered intracoronary adenosine, the incidence of heart failure was significantly lower (risk ratio [RR] 0.44 [95% CI 0.25–0.78], P = 0.005) and the incidence of coronary no-reflow was reduced (RR for TIMI flow<3 postreperfusion 0.68 [95% CI 0.47–0.99], P = 0.04). There was no difference in heart failure incidence in the intravenous adenosine group but most RCTs in this subgroup were from the thrombolysis era. There was no difference in non-fatal MI or all-cause mortality in both subgroups. Conclusion: We find evidence of improved clinical outcome in terms of less heart failure in STEMI patients administered intracoronary adenosine as an adjunct to reperfusion. This finding will need to be confirmed in a large adequately powered prospective RCT
    • …
    corecore